Teva

BioDelivery Sciences names Adrian Hepner vice president

Tuesday, July 30, 2013 12:00 PM

Pharmaceutical company BioDelivery Sciences International (BDSI), headquartered in Raleigh, N.C., has hired Adrian Hepner, M.D., Ph.D., as vice president of clinical research and regulatory affairs. Hepner joins BDSI with over 20 years of experience in U.S. and international clinical research and drug development, including development and implementation of the clinical and regulatory strategy for a number of products from early stage development through NDA and E.U. regulatory filings.

More... »

Teva, Lonza discontinue biosmilar venture

Friday, July 26, 2013 09:30 AM

Teva Pharmaceutical Industries of Jerusalem and Lonza Group, based in Switzerland, have decided to discontinue their joint venture for the development, manufacturing and marketing of biosimilars. The companies said ending the collaboration, which began in 2009, will enable both to better advance their own strategies and efforts.

More... »

Teva, Active Biotech release results from 3-year ALLEGRO study in MS

Friday, March 22, 2013 11:48 AM

Teva Pharmaceutical Industries, a global pharmaceutical company, and Active Biotech, a biotechnology company with focus on autoimmune/inflammatory diseases and cancer, released today top-line results from the open-label extension of the phase III ALLEGRO study that assessed the progression of disability and safety of oral laquinimod in early versus delayed-start relapsing-remitting multiple sclerosis (RRMS) patients.

More... »

NeuroSearch to update its strategy, reduce staff

Wednesday, March 20, 2013 09:39 AM

NeuroSearch’s transfer of the Huntexil project to Teva Pharmaceutical Industries is now so advanced that the company foresees a significant reduction in the activity level in the near future. Therefore, NeruoSearch will take measures to adjust the organization to the lower activity level and at the same time update its company strategy.

More... »

Teva signs new $3B syndicated revolving credit facility

Tuesday, December 18, 2012 02:23 PM

Teva Pharmaceutical Industries, a global pharmaceutical company, has entered into a new five-year, $3 billion unsecured revolving credit facility, which replaces its existing $2.5 billion credit facility.

More... »

Teva, Handok to establish business venture in Korean pharma market

Monday, December 17, 2012 01:41 PM

Teva Pharmaceutical Industries, an Israel-based pharmaceutical company, and Handok Pharmaceuticals, a pharmaceutical/healthcare company in Korea, have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market, currently valued at approximately $14 billion.

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Teva names Oberman as CEO of Teva Americas Generics

Wednesday, November 7, 2012 12:14 PM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has made changes to its executive leadership team.

More... »

Teva Canada completes sale of Mirabel facility to Halo Pharmaceutical

Monday, August 6, 2012 11:38 AM

Teva Canada, a healthcare solutions provider, has completed the sale of its Mirabel manufacturing facility in Montreal to Halo Pharmaceutical, a contract development and manufacturing organization (CDMO) based in Parsippany, N.J.

More... »

Teva appoints two to executive team

Friday, August 3, 2012 11:07 AM

Teva Pharmaceutical, a global pharmaceutical company based in Israel, has appointed Dr. Carlo De Notaristefani as president and CEO of global operations and Aharon (Arik) Yaari as executive vice president of newly created community and institutional affairs.

More... »